Ceramic-on-Ceramic (COC) 36mm Acetabular Bearing Insert Post Approval Study-New Subjects (COC36mmPAS)
Status: | Active, not recruiting |
---|---|
Conditions: | Arthritis, Osteoarthritis (OA), Orthopedic, Orthopedic |
Therapuetic Areas: | Rheumatology, Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 21 - 75 |
Updated: | 12/8/2018 |
Start Date: | June 1, 2014 |
End Date: | September 30, 2024 |
36mm CERAMAX® Ceramic Hip System PMA PAS STUDY: Short to Mid-Term Follow-up , New Study Subjects (Ceramic Hip System, Subjects Receive CERAMAX 36mm Ceramic Acetabular Bearing Insert That Articulates With a Ceramic Femoral Head for THA)
This study is intended to gather short (Pre-operative to 4-years) and mid-term (5-years)
information regarding the performance and safety of the commercially available 36mm CERAMAX®
Ceramic on Ceramic Total Hip System from a cohort of new study subjects that were not
previously involved in the IDE study for this device.
information regarding the performance and safety of the commercially available 36mm CERAMAX®
Ceramic on Ceramic Total Hip System from a cohort of new study subjects that were not
previously involved in the IDE study for this device.
Up to 10 (up to 5 original IDE + 5 new sites)
A prospective, non-controlled, non-randomized, multicenter study. Subjects will be seen for a
clinic visit pre-operatively at the time of consent, (-90 days to surgery) and then at
post-operatively at 6 weeks (1-92 days), 1 year (275-455 days), 2 years (640-820 days) and 3
years (1005-1185days), 4 years (1370-1550 days), and a minimum of 5 years (1825- 2919 days).
Data collected will include: Pre-operatively subject history and demographics; Operative and
device details; and Post-operatively Harris HIp scores, Subject Hip Outcomes, and Adverse
Events.
In order to optimize mid-term follow-up compliance, site personnel are permitted to contact
the study subject in the 3 and 4 year intervals by phone (in place of a clinic visit) to
assess the current status of the hip.
A prospective, non-controlled, non-randomized, multicenter study. Subjects will be seen for a
clinic visit pre-operatively at the time of consent, (-90 days to surgery) and then at
post-operatively at 6 weeks (1-92 days), 1 year (275-455 days), 2 years (640-820 days) and 3
years (1005-1185days), 4 years (1370-1550 days), and a minimum of 5 years (1825- 2919 days).
Data collected will include: Pre-operatively subject history and demographics; Operative and
device details; and Post-operatively Harris HIp scores, Subject Hip Outcomes, and Adverse
Events.
In order to optimize mid-term follow-up compliance, site personnel are permitted to contact
the study subject in the 3 and 4 year intervals by phone (in place of a clinic visit) to
assess the current status of the hip.
Inclusion Criteria:
- Males and females between 21 - 75 at the time of surgery.
- Individuals, who in the opinion of the investigator, are suitable candidates for
primary total hip replacement using the devices specified in this protocol.
- Individuals with non-inflammatory degenerative joint disease (NIDJD) or any of its
composite diagnoses of osteoarthritis, avascular necrosis, and posttraumatic
arthritis.
- Individuals who are willing and able to provide informed patient consent for
participation in the study;
- Individuals who are willing and able to return for follow-up as specified by the study
protocol; and
- Individuals who are willing and able to complete the Subject Hip Outcomes
questionnaire as specified by the study protocol.
Exclusion Criteria:
- Skeletally immature patients (tibial and femoral epiphyses not closed)
- Evidence of active infections that may spread to other areas of the body
(e.g.,osteomyelitis, pyogenic infection of the hip joint, overt infection, urinary
tract infection, etc.)
- The presence of any known neoplastic (tumor-causing) or metastatic (spread of
cancerous cells) disease
- Significant neurologic or musculoskeletal disorders or diseases that may adversely
affect gait, weight bearing or postoperative recovery (e.g., muscular dystrophy,
multiple sclerosis)
- Presence of highly communicable disease(s) that may limit follow-up (e.g.,
immuno-compromised conditions, hepatitis, active tuberculosis, etc.)
- Any condition that may interfere with postoperative recovery (e.g., Paget's disease,
Charcot's disease)
- Inadequate bone stock to support the device (e.g., severe osteopenia orosteoporosis)
- Poor skin coverage around the hip joint
- Use in patients with known allergies to the implant materials
- Marked atrophy (muscle and/or tissue loss) or deformity in the upper femur such as a
birth defect affecting the leg bones.
- Inflammatory degenerative joint disease (like rheumatoid arthritis)
- Subject has participated in an IDE/IND clinical investigation, other than the
COC28/COC36 IDE or PAS for their contralateral hip, with an investigational product in
the last three months.
- Subject is currently involved in a personal injury litigation, medical-legal or
worker's compensation claims.
- Subject is a known drug or alcohol abuser or has a psychological disorder that could
affect their ability to comply with protocol procedures and/or subject-completed
questionnaires.
- The Subject is a woman who is pregnant or lactating.
- The Subject has a medical condition with less than 2 years of life expectancy.
We found this trial at
11
sites
Click here to add this to my saved trials
Boston, Massachusetts
Principal Investigator: Eric Smith, MD
Phone: 617-636-5159
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Durham, North Carolina 27705
Phone: 919-684-6166
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials